F-1: NewGenIvf Group Plans Resale of 5.9 Million Class A Ordinary Shares

NewGenIvf Group Limited is registering for resale up to 5,912,281 Class A Ordinary Shares by selling shareholders to enhance market liquidity.

Summary

• NewGenIvf Group Limited, a British Virgin Islands holding company specializing in assisted reproductive services (ARS) in the Asia-Pacific region, has filed a registration statement for the resale of up to 5,912,281 Class A Ordinary Shares by selling shareholders.
• The company will not receive any proceeds from the sale, as all net proceeds will go to the selling shareholders.
• The purpose of the resale is to enhance liquidity in the public trading market for NewGenIvf's equity securities in the United States.
• NewGenIvf's Ordinary Shares currently trade on The Nasdaq Global Market under the symbol NIVF, with the last reported closing price on August 30, 2024, at $0.86.
• The company operates through subsidiaries in the Cayman Islands and Asia (Hong Kong, Thailand, Kyrgyzstan, and Cambodia), with substantial operations and assets based in Thailand, Cambodia, and Kyrgyzstan.
• Investing in NewGenIvf's Ordinary Shares involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.

Sentiment

Score: 5

Explanation: The document is neutral, primarily providing factual information about the share resale and company operations. It highlights both opportunities and risks, resulting in a balanced sentiment.

Positives

• The resale aims to enhance liquidity in the public trading market for the company's equity securities.
• NewGenIvf has established itself as a long-standing ARS provider in the Asia-Pacific region.
• The company has a strategic presence in Thailand, Cambodia, and Kyrgyzstan.

Negatives

• Investing in NewGenIvf's Ordinary Shares involves a high degree of risk.
• The company's businesses and operations are subject to the changing economic conditions prevailing in Thailand, Cambodia, and Kyrgyzstan.

Risks

• The document highlights risks related to NewGenIvf's business and industry, relationships with third parties, and government regulation.
• Specific risks include the ability to continue as a going concern, competition in the fertility market, and reliance on international clients.
• The company's operations are subject to economic, legal, and regulatory uncertainties in Thailand, Cambodia, and Kyrgyzstan.

Future Outlook

NewGenIvf plans to offer broad fertility services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities, increase brand awareness and market share, and expand service reach through acquisitions and partnerships.

Industry Context

The document notes that the market size of fertility treatments in Asia Pacific is expected to reach US$37.4 billion by 2030, indicating a growing demand for ARS services.

Comparison to Industry Standards

• The document mentions that the average cost per IVF cycle in the US is around US$12,000 (excluding medication), which is 65% higher than that of Asia-Pacific market.
• The average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication).

Stakeholder Impact

• The resale of shares may impact current shareholders through potential dilution or price fluctuations.
• The company's performance and strategic decisions will affect employees, customers, and other stakeholders.

Next Steps

• The selling shareholders may sell their Ordinary Shares from time to time at prevailing market prices.

Key Dates

Keywords

NewGenIvf, Ordinary Shares, Resale, Liquidity, ARS, Fertility, Asia-Pacific, Nasdaq, Risk Factors, Selling Shareholders